Viewing data from:

TESTOSTERONE CYPIONATE

ANDA

TESTOSTERONE CYPIONATE | A040530 | PADAGIS US LLC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Testosterone Cypionate (2023)

Total Spending

$38.0M

Total Claims

935,456

Beneficiaries

242,810

Avg Cost/Unit

$9.30

Spending Trend

$35.7M(2019)→$40.3M(2020)→$40.0M(2021)→$40.3M(2022)→$38.0M(2023)

YoY Change:-17.5%

5yr CAGR:-5.3%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain8 active DMFs3 inactive

8 active API suppliers hold Drug Master Files for this ingredient.

ASPEN OSS BVTESTOSTERONE CYPIONATE

DMF 38571980

PHARMACIA AND UPJOHN CO LLC WHOLLY OWNED SUB OF PFIZER INCTESTOSTERONE CYPIONATE USP

DMF 42451981

TRIFARMA SPATESTOSTERONE CYPIONATE USP

DMF 210912007

SYMBIOTEC PHARMALAB PRIVATE LTDTESTOSTERONE CYPIONATE USP

DMF 290232015

CURIA SPAIN SAUTESTOSTERONE CYPIONATE

DMF 318602017

STEROID SPATESTOSTERONE CYPIONATE

DMF 329322018

FARMABIOS SPATESTOSTERONE CYPIONATE

DMF 423052025

HUBEI ZHUXI HUMANWELL PHARMACEUTICAL CO LTDTESTOSTERONE CYPIONATE

DMF 424972025

DIOSYNTH BVInactiveTESTOSTERONE CYPIONATE

DMF 29941977

ROUSSELL UCLAFInactiveTESTOSTERONE CYPIONATE

DMF 32201978

FIS FABBRICA ITALIANA SINTETICI SPAInactiveTESTOSTERONE CYPIONATE

DMF 334112018

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 200MG/ML

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Jan 31, 2005

No patent or exclusivity listings for this strength.